DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20163218

A comparative prospective study to assess the clinical efficacy and safety of pantoprazole monotherapy versus pantoprazole and itopride dual therapy in patients with gastroesophageal reflux disease in a tertiary care hospital

Pradeep Kumar BT, Mamatha KR, Nagesh NS, Jayanthi CR, Bharath Kumar VD

Abstract


Background: Gastroesophageal reflux disease (GERD) is a common chronic, relapsing condition that carries a risk of significant morbidity and potential mortality from resultant complications. Proton pump inhibitors (PPIs) remained as the main stay in the therapy of GERD but they do not have any role in increasing the tone of lower esophageal sphincter which is the main pathophysiology of GERD. In this regard addition of prokinetic agent like Itopride may be beneficial in improving the symptoms associated with GERD. So the present study has been taken to compare the healing rates of esophagitis and reduction in symptom scores associated with GERD between Pantoprazole monotherapy and Pantoprazole plus Itopride combination.

Methods: 100 patients diagnosed with GERD were randomly assigned into two groups, Group A and Group B. Group A received tablet Pantoprazole 40 mg twice daily alone and group B received tablet Pantoprazole 40 mg twice daily and tablet Itopride 50 mg thrice daily 30 minutes before food for 4 weeks. The patients were followed up at the end of 4 weeks and were given the questionnaire to assess the FSSG scores. Endoscopy and FSSG scores were recorded and then the percentage of responders in both groups was compared.

Results: Endoscopic evidence of healing of esophagitis was similar in both the groups, 72% in Group A and 74% in Group B. The symptom relief was significantly more in Pantaprozole plus Itopride group 74.5% (4.2±1.6) than Pantaprozole alone 62.5% (6.4±1.1) after 4 weeks (p < 0.001).The occurrence of side effects was less in group B compared to group A (22% vs 30%, p= 0.172).

Conclusions: Pantoprazole and combination of Pantoprazole plus Itopride provide more effective endoscopic healing of esophagitis. Pantoprazole and Itopride combination is more efficacious in ameliorating the symptoms of GERD than Pantoprazole alone.


Keywords


Pantoprazole, GERD, LES, Itopride, PPIs, Prokinetics, Esophagitis, FSSG scores

Full Text:

PDF

References


Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13:49-57.

Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol. 2001;13(1):5-11.

Kumar S, Sharma S, Norboo T, Dolma D, Norboo A, Stobdan T, et al. Population based study to assess prevalence and risk factors of gastroesophageal reflux disease in high altitude area. Indian society of Gastroenterology. 2010;30(3):135-43.

Kim YS, Kim TH, Choi CS, Shon YW, Kim SW, Seo GS, et al.Effect of itopride new prokinetic in patients with mild GERD: A pilot study. World J Gastroenterology. 2005;11(27):4210-4.

Lundell L, Myers JC, Jamieson GG. Is motility impaired in the entire upper gastrointestinal tract in patients with gastrooesophageal reflux disease? Scand J Gastroenterol. 1996;31:131-5.

Rydberg L, Ruth M, Lundell L. Does oesophageal motor function improve with time after successful antireflux surgery? Results of a prospective, randomized clinical study. Gut. 1997;41:82-6.

Hoogerwerf WA, Pasricha PJ. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gillman’s The Pharmacological Basis of Therapeutics.11th ed. New York, McGraw hill; 2006: 1309-1322.

Chandrasoma P. The Pathology of Gastroesophageal Reflux Disease. In: Yeo CJ, Dempesy DT, Klein AS, Pemberton JH, Peters JH, Eds. Shackelford’s Surgery of the Alimentary Tract. 6th ed. Elsevier; 2012: 560-580.

Modlin IM, Borteçen KH, Sandor A, et al. Solving the GORDian knot. In: Büchler MW, Frei E, Klaiber Ch, et al. eds. Gastroesophageal reflux disease (GERD): back to surgery? Basel, Switzerland. Karger; 1997: 60-70.

Scarpellini E, Vos R, Blondeau K, Boecxstaens V, Boecxstaens V, Farré R, Gasbarrini A, et al. The effect of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol and Ther. 2011;33:99-105.

Singhal S, Dhawan P, Bhatt A, Pokharna R, Sharma D, Kumar G, et al. Evaluation of Safety and Efficacy of Pantoprazole and Domperidone Combination in Patients with Gastroesophageal Reflux Disease. The Internet Journal of Gastroenterology. 2006;4(2):1-5.

Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004;17:274-8.

Krishnakanth K, Siddalingappa CM, Kudagi BL. Efficacy of pantaprozole versus pantaprozole plus itopride in gastroesophageal reflux disease patients - A pilot study. Indian journal of Pharmacology. 2011;43:205-8.

Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. N Eng J Med. 1995;333:1106-10.

Robinson MG, Orr WC, McCallum R, Nardi R. Do endoscopic findings influence response to H2 antagonist therapy for gastroesophageal reflux disease. Am J Gastroenterol. 1987;82:519-22.

Bochenek WJ, Mack ME, Fraga PD and Metz DC. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Aliment Pharmacol Ther. 2004;20:1105-14.